Nicholas A Butowski
Overview
Explore the profile of Nicholas A Butowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
2641
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez Almaraz E, Guerra G, Al-Adli N, Young J, Dada A, Quintana D, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf024.
PMID: 40051658
Background: Isocitrate dehydrogenase (IDH)-mutant astrocytomas represent the most frequent primary intraparenchymal brain tumor in young adults, which typically arise as low-grade neoplasms that often progress and transform to higher grade...
2.
Venneti S, Kawakibi A, Ji S, Waszak S, Sweha S, Mota M, et al.
Cancer Discov
. 2025 Mar;
15(3):657.
PMID: 40025951
No abstract available.
3.
Lucas C, Al-Adli N, Young J, Gupta R, Morshed R, Wu J, et al.
Neuro Oncol
. 2024 Nov;
27(1):89-105.
PMID: 39560080
Background: Despite recent advances in the biology of IDH-wildtype glioblastoma, it remains a devastating disease with median survival of less than 2 years. However, the molecular underpinnings of the heterogeneous...
4.
Sarkaria J, Ballman K, Kizilbash S, Sulman E, Giannini C, Friday B, et al.
JAMA Oncol
. 2024 Oct;
10(12):1637-1644.
PMID: 39480453
Importance: The prognosis for patients with glioblastoma is poor following standard therapy with surgical resection, radiation, temozolomide, and tumor-treating fields. Objectives: To evaluate the combination of veliparib and temozolomide in...
5.
Liu J, Jakary A, Villanueva-Meyer J, Butowski N, Saloner D, Clarke J, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672606
This study aimed to develop a rapid, 1 mm isotropic resolution, whole-brain MRI technique for automatic lesion segmentation and multi-parametric mapping without using contrast by continuously applying balanced steady-state free...
6.
Hadad S, Gupta R, Oberheim Bush N, Taylor J, Villanueva-Meyer J, Young J, et al.
Acta Neuropathol
. 2023 Dec;
147(1):3.
PMID: 38079020
Glioblastoma is a clinically and molecularly heterogeneous disease, and new predictive biomarkers are needed to identify those patients most likely to respond to specific treatments. Through prospective genomic profiling of...
7.
Gibson D, Ravi A, Rodriguez E, Chang S, Oberheim Bush N, Taylor J, et al.
Neurooncol Adv
. 2023 Oct;
5(1):vdad115.
PMID: 37899778
Background: Epigenetic inhibition of the () gene has emerged as a clinically relevant prognostic marker in glioblastoma (GBM). Methylation of the promoter has been shown to increase chemotherapy efficacy. While...
8.
Saijo A, Ogino H, Butowski N, Tedesco M, Gibson D, Watchmaker P, et al.
Neuro Oncol
. 2023 Sep;
26(2):335-347.
PMID: 37758193
Background: Central nervous system (CNS) WHO grade 2 low-grade glioma (LGG) patients are at high risk for recurrence and with unfavorable long-term prognosis due to the treatment resistance and malignant...
9.
Venneti S, Kawakibi A, Ji S, Waszak S, Sweha S, Mota M, et al.
Cancer Discov
. 2023 Aug;
13(11):2370-2393.
PMID: 37584601
Significance: The clinical, radiographic, and molecular analyses included in this study demonstrate the efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to improve outcomes in...
10.
Lucas C, Sloan E, Gupta R, Wu J, Pratt D, Vasudevan H, et al.
Acta Neuropathol
. 2022 Aug;
144(4):747-765.
PMID: 35945463
Gliomas arising in the setting of neurofibromatosis type 1 (NF1) are heterogeneous, occurring from childhood through adulthood, can be histologically low-grade or high-grade, and follow an indolent or aggressive clinical...